1. How Much Does CAR-T Therapy Cost in China? (2026)
CAR-T therapy in China has two distinct price tiers depending on how you access it. This is why quotes for the same product can differ by 3-5x between patients.
Two Price Tiers Explained
| Access Route | 2026 Price (USD) | Best For |
|---|---|---|
| Commercial (NMPA-approved product) | $89K – $151K | Patients who want a specific approved product, no trial eligibility required |
| Clinical trial / sponsored access | $30K – $80K | Eligible patients willing to enroll in a hospital- or manufacturer-sponsored trial |
Both tiers are 60-85% below US prices. Travel and accommodation are not included in either figure. All estimates are 2026 estimates based on published data; final cost depends on hospital and clinical complexity.
China vs US vs Singapore vs India vs EU (Commercial Products)
| Therapy / Country | China (Commercial) | USA | Singapore | India | EU (Germany) |
|---|---|---|---|---|---|
| Axicabtagene ciloleucel (Yescarta) | $89K – $130K | $424K | Not approved for sale | Not approved | $320K – $400K |
| Tisagenlecleucel (Kymriah) | $100K – $150K | $475K | $280K – $350K | Not approved | $300K – $380K |
| Relmacabtagene (Carteyva) | $89K – $120K | N/A (China-only) | N/A | N/A | N/A |
| Satri-cel (Claudin18.2, gastric) | $89K – $170K | N/A | N/A | N/A | N/A |
Note: Carteyva is China-domestic and not available outside China. Satri-cel is the world's first approved solid-tumor CAR-T (gastric/GEJ adenocarcinoma, NMPA approval June 2026).
Full Trip Budget for International CAR-T Patients
Beyond the drug and hospital fees, patients need to budget for:
| Item | Estimated Cost (USD) |
|---|---|
| Medical visa + invitation letter | $0 – $140 |
| Round-trip flights (Asia → China) | $400 – $1,500 |
| Hospital deposit (payable on admission) | 50% of quoted CAR-T cost |
| Hospital stay (4-6 weeks inpatient + monitoring) | Included in CAR-T package |
| Companion accommodation | $1,500 – $4,000 |
| Translator / medical coordinator | $500 – $2,000 |
| Post-treatment follow-up scans (3, 6, 12 months) | $1,000 – $3,000 |
| Total trip (excluding CAR-T) | $3,500 – $10,500 |
Patients from Singapore, Indonesia, Vietnam, Thailand, and Russia typically spend $3,500-6,500 on logistics. Patients from the Middle East, Africa, Europe, and the Americas typically spend $6,500-10,500.
2. Top 5 Hospitals for CAR-T Therapy in China
All listed hospitals have dedicated hematology / oncology centers with international patient departments and English-speaking coordinators.
1. Ruijin Hospital — Shanghai Jiao Tong University School of Medicine
City: Shanghai | Specialty rank: #1 hematology in China (Fudan Ranking)
- One of the largest CAR-T programs in Asia; established hematologic and solid-tumor track record
- Strongest portfolio: CD19 (Carteyva, Yescarta), BCMA (multiple myeloma)
- International department: dedicated English team, visa invitation letters in 48 hours
- Cost range: $89K – $130K (commercial); trial slots frequently open for relapsed DLBCL and ALL
2. Peking University Cancer Hospital
City: Beijing | Specialty rank: Top 3 oncology nationally
- Satri-cel (Claudin18.2) commercial launch site; gastric / GEJ adenocarcinoma
- Lymphoma and leukemia CAR-T programs co-located
- International department: visa support, English / Arabic / Russian coordinators
- Cost range: $89K – $170K for satri-cel; $89K – $120K for hematologic CAR-T
3. Jiahui International Hospital (Shanghai)
City: Shanghai | Specialty rank: International-standard private hospital
- Satri-cel commercial launch site (June 2026)
- Caters to international and Middle Eastern patients; halal meals, prayer space
- Cost range: $110K – $170K for satri-cel; bundled pricing includes coordinator
- Best for: patients prioritizing English / Arabic / Russian-speaking care
4. Chinese PLA General Hospital (301 Hospital)
City: Beijing | Specialty rank: Top 5 oncology; large CAR-T volume
- Strong hematologic and solid-tumor CAR-T trial pipeline
- Military hospital — international patient access restricted to civilian-approved indications; verify eligibility before applying
- Cost range: $89K – $140K (commercial); trial pricing varies
5. Tongji Hospital — Huazhong University of Science & Technology
City: Wuhan | Specialty rank: Top 10 hematology
- High-volume hematologic malignancy program; lower pricing than Tier-1 cities
- International patient department: English and Russian support
- Cost range: $75K – $115K (commercial); some of the most competitive hematologic CAR-T pricing
3. Why China for CAR-T Therapy?
| Factor | Detail |
|---|---|
| Approval volume | 7 NMPA-approved CAR-T products as of mid-2026 — more than the US (6) or EU (5). Satri-cel (June 2026) is the world's first solid-tumor CAR-T. |
| Cost advantage | 60-85% below US prices for the same or equivalent products. Carteyva (relmacabtagene) is China-domestic and priced at the lower band. |
| Trial access | 500+ active CAR-T clinical trials — the largest pipeline globally. Trial slots exist for Claudin18.2, GPC3, mesothelin, claudin6, EGFRvIII, and next-generation armored CAR constructs. |
| No waitlist | Most commercial CAR-T slots can be booked within 2-4 weeks of confirmed eligibility. Trial enrollment typically 4-8 weeks. |
| JCI / NMPA standards | Top oncology centers are JCI-accredited or NMPA-certified cellular therapy facilities, with cGMP manufacturing on-site or via contracted partners. |
| Hospital volume | Tier-1 hematology centers perform 200-400+ CAR-T infusions per year — comparable to MD Anderson or Memorial Sloan Kettering. |
4. How International Patients Arrange CAR-T in China
Step 1 — Submit records for eligibility review (free) Send recent (within 3 months) pathology report, target antigen status (CD19 / BCMA / Claudin18.2 / GPC3), imaging, and ECOG performance status. We route your case to the right oncology center within 48 hours.
Step 2 — Receive commercial quote + trial options The hospital issues a written commercial quote (typically 7-10 working days). If eligible, parallel trial options are listed with their consent requirements.
Step 3 — Choose route and pay deposit For commercial: pay 30-50% deposit to lock the manufacturing slot. For trial: sign informed consent; trial-related CAR-T product and partial hospitalization may be sponsored.
Step 4 — Visa and travel Hospital issues medical visa invitation letter (M visa or visa-free entry for eligible nationalities). Average total time from approval to admission: 2-4 weeks.
Step 5 — Apheresis, manufacturing, conditioning, infusion Standard CAR-T timeline: 1 day apheresis → 2-4 weeks manufacturing → 3-5 days lymphodepleting chemo → 1 day infusion → 10-14 days inpatient monitoring. Total China stay: 4-6 weeks.
Step 6 — Local follow-up and return Discharge with 30-day medication plan. International patients typically have local hematologist / oncologist handle post-return monitoring, with tele-consults to the China team for the first year.
5. Frequently Asked Questions
How much does CAR-T therapy cost in China in 2026?
Commercial CAR-T in China costs $89,000 – $151,000 for hematologic products (CD19, BCMA) and $89,000 – $170,000 for satri-cel (Claudin18.2, solid tumor). Clinical trial access can drop pricing to $30,000 – $80,000 for eligible patients. Compared to $300,000-$500,000 in the US, China is 60-85% cheaper. (2026 estimates based on published data; final cost depends on hospital and clinical complexity.)
Is CAR-T therapy in China safe?
Yes — at JCI-accredited centers such as Ruijin Hospital, Peking University Cancer Hospital, and Jiahui International Hospital. These centers perform 200-400+ CAR-T infusions per year with outcomes comparable to international standards. All commercial products are NMPA-approved; trial products follow ICH-GCP guidelines. International patient departments provide English-speaking care, ICU monitoring, and cytokine release syndrome (CRS) management on-site.
What are the best hospitals in China for CAR-T therapy?
The top hospitals for CAR-T in China are: 1) Ruijin Hospital, Shanghai (top hematology); 2) Peking University Cancer Hospital, Beijing (top oncology, satri-cel launch site); 3) Jiahui International Hospital, Shanghai (international-standard private); 4) 301 Hospital, Beijing (high volume, military); 5) Tongji Hospital, Wuhan (competitive pricing). All five have international patient departments with English-speaking staff and visa support.
How long does the full CAR-T process take in China?
The standard CAR-T timeline is 4-6 weeks in China: 1 day for apheresis (T-cell collection), 2-4 weeks for manufacturing, 3-5 days for lymphodepleting chemotherapy, 1 day for infusion, and 10-14 days for inpatient monitoring. Add 2-4 weeks on either side for visa, travel, and pre-admission tests.
Can clinical trials cut the cost of CAR-T in China?
Yes — clinical trial access can drop the CAR-T product cost to $30,000 – $80,000, with most trials covering the CAR-T product itself and partial hospitalization. Eligibility depends on antigen status, prior treatment lines, ECOG performance, and organ function. Trial slots are most available for Claudin18.2 (gastric), CD19 (relapsed DLBCL, ALL), and BCMA (multiple myeloma).